Loading, please wait....jpg)
.jpg)
CONTINUING PHARMACY EDUCATION
Pharmacy Considerations for the Optimal Utilization of T-Cell Engaging Bispecific Antibodies
for Hematologic Malignancies
Speaker: Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, Clinical Oncology Pharmacy Manager, Pharmacy Services - Levine Cancer Institute, Atrium Health, Charlotte, NC
ACPE Universal Program ID# 0122-0000-25-053-H01-P/T
1 Contact Hours [0.1 CEU]
Release Date: September 8, 2025
Expiration Date: September 8, 2028
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists and Pharmacy Technicians
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Review the pharmacology and indications of recently approved T-cell engaging bispecific antibodies for the treatment of hematologic malignancies
- Evaluate efficacy data supporting the approval of bispecific antibodies for multiple myeloma and lymphomas
- Describe supportive care strategies to prevent and manage adverse events associated with bispecific antibodies
- Define best practices for pharmacies to overcome administration and operational challenges associated with bispecific antibodies
Activity Number
0122-0000-25-053-H01-P/T
Release Date:
Sep 8, 2025
Credit Expiration Date:
Sep 8, 2028
CE Hours
1.00